Search results
Showing 851 to 900 of 3030 results for all
Panobinostat for treating multiple myeloma after at least 2 previous treatments (TA380)
Evidence-based recommendations on panobinostat (Farydak) for treating multiple myeloma after at least 2 previous treatments.
View recommendations for TA380Show all sections
Alitretinoin for the treatment of severe chronic hand eczema (TA177)
Evidence-based recommendations on alitretinoin (Toctino) for treating severe chronic hand eczema in adults.
Evidence-based recommendations on trifluridine–tipiracil (Lonsurf) for treating metastatic gastric cancer or gastro-oesophageal junction adenocarcinoma in adults after 2 or more treatments.
Evidence-based recommendations on durvalumab (Imfinzi) for locally advanced unresectable non-small-cell lung cancer after platinum-based chemoradiation in adults.
This quality standard covers diagnosing, managing and treating rare diseases in children, young people and adults. It describes high-quality care in priority areas for improvement.
View quality statements for QS214Show all sections
Sections for QS214
- Quality statements
- Quality statement 1: Referral for investigation and treatment
- Quality statement 2: Undiagnosed conditions
- Quality statement 3: Information provision
- Quality statement 4: Shared decision making
- Quality statement 5: Named healthcare professional
- Quality statement 6: Holistic needs assessment
- Quality statement 7: Access to treatment
This quality standard covers care and support and services for children, young people and adults with a learning disability (or a learning disability and autism) and behaviour that challenges, and their families and carers. It describes high quality care in priority areas for improvement.
View quality statements for QS101Show all sections
Sections for QS101
- Quality statements
- Quality statement 1: Lead commissioner
- Quality statement 2: Annual health check
- Quality statement 3: Initial assessment of behaviour that challenges
- Quality statement 4: Named lead practitioner
- Quality statement 5: Involving families and carers
- Quality statement 6: Parent-training programmes
- Quality statement 7: Personalised daily activities
Evidence-based recommendations on rivaroxaban (Xarelto) for preventing atherothrombotic events, such as heart attack and stroke, after acute coronary syndrome in adults.
This guideline covers care before, during and after a planned knee, hip or shoulder replacement. It includes recommendations to ensure that people are given full information about their options for surgery, including anaesthesia. It offers advice for healthcare professionals on surgical procedures and ensuring safety during operations. It also offers guidance on providing support and rehabilitation before and after surgery.
Evidence-based recommendations on point-of-care creatinine devices to assess kidney function before CT imaging with intravenous contrast. The tests are ABL800 FLEX, i-STAT Alinity and StatSensor, ABL90 FLEX PLUS, Dri chem NX500, epoc Blood Analysis System, and Piccolo Xpress.
This indicator covers the percentage of patients with diabetes, on the register, with a diagnosis of nephropathy (clinical proteinuria) or micro-albuminuria who are currently treated with an ACE-I (or ARBs). It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes. This indicator was previously published as NM95.
things that are important to you. Talk to your healthcare professional about all your concerns so that you can make an informed choice....
Developmental follow-up of children and young people born preterm (QS169)
This quality standard covers the developmental follow-up of babies, children and young people under 18 years who were born preterm (before 37+0 weeks of pregnancy). It describes high-quality care in priority areas for improvement.
This quality standard covers diagnosing and managing lower urinary tract symptoms in men (aged 18 and over). It describes high-quality care in priority areas for improvement.
View quality statements for QS45Show all sections
Sections for QS45
- Quality statements
- Quality statement 1: Initial assessment – physical examination
- Quality statement 2: Initial assessment – urinary frequency and volume chart
- Quality statement 3: Initial assessment – advice on lifestyle interventions
- Quality statement 4: Conservative management – temporary containment products
- Quality statement 5: Conservative management – urethral milking
- Quality statement 6: Medication review
- Quality statement 7: Specialist assessment – flow rate and post-void residual volume
This guideline covers nutrition and weight management in pregnancy for anyone who may become pregnant, is planning to become pregnant or is already pregnant, and nutrition in children up to 5 years. Care of babies and children born preterm or with low birth weight is not covered. The guideline does not give detailed advice on what constitutes a healthy diet.
Evidence-based recommendations on pembrolizumab (Keytruda) for treating locally advanced or metastatic urothelial carcinoma after platinum-containing chemotherapy in adults.
Research to access pathway for investigational drugs for COVID-19 (RAPID C-19)
RAPID C-19’s role in reviewing potential COVID-19 treatments has now ended because we have moved back to routine commissioning arrangements for these treatments.
Evidence-based recommendations on pembrolizumab (Keytruda) for relapsed or refractory classical Hodgkin lymphoma in people 3 years and over.
Evidence-based recommendations on mepolizumab (Nucala) for add-on maintenance treatment of uncontrolled chronic obstructive pulmonary disease (COPD) with raised blood eosinophils in adults.
Evidence-based recommendations on the Foker technique for long-gap oesophageal atresia. This involves pulling slightly on the broken ends of the oesophagus to encourage them to grow towards each other so they can be stitched together to form a complete oesophagus.
View recommendations for HTG98Show all sections
agent used and the duration of thrombolysis should be reported, together with all complications. Outcome measures should include the...
Read the biographies for all members of the NICE antimicrobial evaluation committee.
Read the biographies for all members of the NICE antimicrobial evaluation committee.
Evidence-based recommendations on lutetium (177Lu) oxodotreotide (Lutathera) for treating unresectable or metastatic neuroendocrine tumours in adults.
Evidence-based recommendations on the bisphosphonates alendronic acid, ibandronic acid, risedronate sodium and zoledronic acid for treating osteoporosis.
Evidence-based recommendations on pembrolizumab (Keytruda) with platinum- and fluoropyrimidine-based chemotherapy for untreated advanced oesophageal and gastro-oesophageal junction cancer in adults.
Evidence-based recommendations on interferon alfa (Pegasys or ViraferonPeg) and ribavirin for people with chronic hepatitis C.
This quality standard covers prevention, behavioural management, assessment, and treatment of overweight, obesity and central adiposity in children and young people aged over 2 years, and adults. This includes those with established comorbidities, and those with risk factors for other medical conditions. It describes high-quality care in priority areas for improvement.
View quality statements for QS212Show all sections
Sections for QS212
- Quality statements
- Quality statement 1: Recording BMI and waist-to-height ratio in adults
- Quality statement 2: Recording BMI in children and young people aged over 2 years
- Quality statement 3: Access to services for people with a learning disability
- Quality statement 4: Maintaining details of local and national overweight and obesity management interventions and services
- Quality statement 5: Providing information about local and national weight management interventions and services
- Quality statement 6: Wraparound care alongside medicines for weight management
- Quality statement 7: Advice and support after stopping medicines for weight management or completing behavioural interventions
Evidence-based recommendations on brolucizumab (Beovu) for diabetic macular oedema in adults.
Cannabidiol with clobazam for treating seizures associated with Dravet syndrome (TA614)
Evidence-based recommendations on cannabidiol (Epidyolex) with clobazam for seizures associated with Dravet syndrome in people aged 2 years and older.
Evidence-based recommendations on tisotumab vedotin (Tivdak) for treating recurrent or metastatic cervical cancer that has progressed on or after systemic treatment in adults.
Show all sections
agent used and the duration of thrombolysis should be reported, together with all complications. Outcome measures should include the...
Evidence-based recommendations on natalizumab originator (Tysabri) and biosimilar (Tyruko) for treating highly active relapsing–remitting multiple sclerosis after disease-modifying therapy in adults.
Evidence-based recommendations on avatrombopag (Doptelet) for treating severe thrombocytopenia in adults with chronic liver disease needing a planned invasive procedure.
Evidence-based recommendations on atezolizumab (Tecentriq) for untreated extensive-stage small-cell lung cancer in adults.
This guideline covers parenteral nutrition (intravenous feeding) for babies born preterm, up to 28 days after their due birth date and babies born at term, up to 28 days after their birth. Parenteral nutrition is often needed by preterm babies, critically ill babies, and babies who need surgery.
Dapagliflozin in combination therapy for treating type 2 diabetes (TA288)
Evidence-based recommendations on dapagliflozin (Forxiga) given with other drugs for treating type 2 diabetes in adults.
Rifaximin for preventing episodes of overt hepatic encephalopathy (TA337)
Evidence-based recommendations on rifaximin (Targaxan) for preventing episodes of hepatic encephalopathy in adults.
Evidence-based recommendations on pemetrexed (Alimta) for locally advanced or metastatic non-squamous non-small-cell lung cancer in adults who have had pemetrexed and cisplatin.
We support the wellbeing of our staff in a number of ways including an employee assistance programme, mental health first aiders and a variety of health and wellbeing activities.
Evidence-based recommendations on epcoritamab (Tepkinly) for treating relapsed or refractory diffuse large B-cell lymphoma in adults after 2 or more systemic treatments.
Ledipasvir–sofosbuvir for treating chronic hepatitis C (TA363)
Evidence-based recommendations on ledipasvir–sofosbuvir (Harvoni) for treating some types (genotypes) of chronic hepatitis C.
us"}}]} Structure of NICE NICE is an organisation made up of people who all share the same mission: helping practitioners and...
system for adjuvant treatment of early breast cancer, TA501 c NICE 2018. All rights reserved. Subject to Notice of rights. Last updated...
Insertion of an epiretinal prosthesis for retinitis pigmentosa (HTG372)
Evidence-based recommendations on insertion of an epiretinal prosthesis for retinitis pigmentosa. This involves inserting an implant into the eye that receives data from a small camera on the person's glasses and then stimulates healthy cells in the retina to see basic images.
Evidence-based recommendations on cytoreduction surgery with hyperthermic intraoperative peritoneal chemotherapy for peritoneal carcinomatosis. This involves surgically removing visible cancer and bathing the abdominal cavity with heated chemotherapy fluid to reach any remaining cancer cells.
View recommendations for HTG569Show all sections
Surgery for uterine prolapse Patient decision aid ? 1 c NICE 2019. All rights reserved. Subject to Notice of rights. Last updated April...
Evidence summaries: new medicines – Integrated process statement (PMG11)
This integrated process statement has been produced to explain how 'Evidence summaries: new medicines' (ESNMs) are developed. It provides an overview of the key process principles and describes all stages of the development of ESNMs
This guideline covers the diagnosis and management of tension-type headache, migraine (including migraine with aura and menstrual-related migraine), cluster headache and medication overuse headache in young people (aged 12 years and older) and adults. It aims to improve the recognition and management of headaches, with more targeted treatment to improve the quality of life for people with headaches, and to reduce unnecessary investigations.
Tofersen for treating amyotrophic lateral sclerosis caused by SOD1 gene mutations [ID3767]
In development Reference number: GID-HST10062 Expected publication date: 17 March 2027
the procedure with conventional stent graft endovascular aneurysm repair. All complications should be reported. Long-term outcomes...